CXCR3 and Duchenne muscular dystrophy: Furthermore, IFN-β, a first-line DMD therapy for RRMS returns the frequency of Th1-like CXCR3+ Tregs to that of healthy controls and increases the frequency of Th17 suppressive Tregs [59].